Short Interest in Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Declines By 71.7%

Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) was the recipient of a large drop in short interest in February. As of February 28th, there was short interest totalling 147,400 shares, a drop of 71.7% from the February 13th total of 520,300 shares. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.7% of the shares of the stock are sold short.

Hedge Funds Weigh In On Inspira Technologies Oxy B.H.N.

An institutional investor recently raised its position in Inspira Technologies Oxy B.H.N. stock. Renaissance Technologies LLC grew its holdings in shares of Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) by 142.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,622 shares of the company’s stock after buying an additional 21,532 shares during the quarter. Renaissance Technologies LLC owned 0.29% of Inspira Technologies Oxy B.H.N. worth $37,000 at the end of the most recent quarter. 12.72% of the stock is currently owned by institutional investors and hedge funds.

Inspira Technologies Oxy B.H.N. Price Performance

IINN traded up $0.03 during trading on Friday, hitting $0.73. The company’s stock had a trading volume of 138,260 shares, compared to its average volume of 1,421,372. Inspira Technologies Oxy B.H.N. has a twelve month low of $0.65 and a twelve month high of $2.45. The firm’s 50 day moving average price is $0.92 and its 200-day moving average price is $1.13. The company has a current ratio of 2.23, a quick ratio of 2.13 and a debt-to-equity ratio of 0.09.

About Inspira Technologies Oxy B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.